Sat, Feb 28, 2015, 2:51 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • edvoks edvoks Feb 4, 2013 10:03 PM Flag

    Akanz, it isn't just about lowering Trigs, it is the EPA

    I'll make this thread to post the scientific literature indicating that EPA is active in reducing the effects of atherosclerosis, reducing arterial calcification as well as the other CV markers that EPA reduces, C-reactive protein, apo-B, lp-PLA2... Let's not just focus on trigs.

    "In other words, the more EPA in the plaque, the less inflamed and more stable it is," said Calder.

    Google this-
    "Omega-3 fatty acids enter plaque, resulting in increased stability and less inflammation"
    Article at the Heart org that I mentioned before.

    Read and understand, let it sink in, the DHA uptake into the plaque was non-significant.

    The EPA was significantly taken into plaque, 100% increase.

    The more EPA in the plaque, the more stable and less inflamed.

    Right there TELLS ME, I want EPA if I have a risk for plaque formation in my arteries.

    Read excerpt below

    Investigators report that EPA and DHA were rapidly taken up into the plaque. There was a significant 100% increase in EPA content in the plaque in patients supplemented with omega-3 fatty acids, but only a 10% nonsignificant increase in the uptake of DHA in the atherosclerotic plaque. The number of foam cells was significantly lower in those treated with fatty acids vs those randomized to placebo.

    Calder noted that a combined mean score, a composite summed measure that includes the size of the lipid core, number of foam cells, and number of macrophages in the plaque and the cap, as well as the overall density of inflammation in the plaque and cap, was lower among patients treated with omega-3 fatty acids. The mean score was significantly negatively correlated with plaque EPA, he reported.

    "In other words, the more EPA in the plaque, the less inflamed and more stable it is," said Calder.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "C-reactive protein and the biology of disease."

      Just out this Feb in the journal "Immunologic Research"

      And here is another new one for March, journal "Blood Coagulation and Fibrinolysis"

      "Increased platelet activation and inflammatory response in patients with masked hypertension."

      There was a significant positive correlation between MPV and CRP levels (P 

      • 1 Reply to edvoks
      • Dr.Barry Sears of Zone-Diet,best seller and a Ph.d. was affliated with MIT---believes strongly that AA/EPA ratio is very early warning indicator of Inflammation--He told me that C-RP level rises much later after AA/EPA indicator.
        He thinks--Reduce-It should use more than 4 gram/day of EPA .
        He told me that he has used 10mg./day of EPA for some people without side effects.
        He sent me an article from 2011 in Atherosclerosis that shows JELIS success in reducing Inflammation.
        It is true that Vascepa reduces TG--but the true benefits in REDUCING CORONARY EVENTS will come from its ability to lower h-C-RP.
        Dr.Topol ,top Cardiologist ,used to be Chief at the Cleveland Clinic--thinks C-RP test is far better than Lipid tests in predicting HEART ATTACKS.
        Astra Zeneca designed Jupiter study with 15000 persons with median C-rp of 4.3.
        70% had C-rp over 3.0--- considered a danger point.
        Jupiter Study produced great reductions--FDA approved New Label after 18 months data in 2009-2010.
        When Reduce-IT study is 100% enrolled--probably by the end of 2013--Expect revelations of similar NEWS in late 2015.
        Dr.Sears told me 6 gram/day or 8 gram/day could produce GREAT RESULTS by end of 2014.

    • Google this one

      "Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes."

      "Multiple regression analysis showed that the administration of EPA was a significant and independent factor associated with an annual improvement of mean IMT (R2=0.067). In summary, this is the first demonstration that administration of purified EPA improves the carotid IMT and the baPWV in patients with type 2 diabetes."

    • Google this
      "Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats."

      "These observations indicate that EPA attenuates arterial medial calcification through an effect associated with the suppression of MMP-9 activity and inhibition of macrophage infiltration as well as osteogenic protein expression in warfarin-induced rat models"

      • 1 Reply to edvoks
      • Ed
        I appreciate your enthusiasm but the Cardiologist I know are not prescribing on the basis of some trial with rats or theories on LDL oxidation .
        They simply want outcome data from a double blinded trail with US patients .....thus the importance of the Reduce it Trial.

        My wife ( a PA authorized to prescribe thinks MD 's will be cautious after the failure of Niacin ) the way one of her patients today ....HDL of 17. , TG over 300 , diabetic and now with kidney failure ....whoa


    • Vascepa reduces lp-PLA2 20% when used with statin compared to statin alone.

      This was linked at StockTwits,
      Search google for

      LpPLA2 explained at YouTube

      Watch the video

      "LpPLA2 is an enzyme that causes hydrolysis of oxidized LDL in the intima generating pro-inflammatory mediators and a variety of inflammatory stimuli associated with atherosclerosis."

    • Now Google this one
      "Data suggest DHA and EPA have differential effects on LDL-cholesterol levels "

      They have different effects on LDL,

      EPA inhibited lipid hydroperoxide (LOOH) formation by 42% and 54% in vesicles with normal AND elevated cholesterol levels, respectively. DHA, on the other hand, inhibited LOOH by 28% in vesicles with elevated cholesterol levels ONLY.

      Read excerpt below


      "One of the things that affect LDL clearance is its oxidative state. Oxidized LDL is not cleared. One of the concepts is that EPA might preferentially prevent LDL oxidation, so even though it's not affecting its synthesis, it would help its clearance."

      EPA inhibited lipid hydroperoxide (LOOH) formation by 42% and 54% in vesicles with normal and elevated cholesterol levels, respectively. DHA, on the other hand, inhibited LOOH by 28% in vesicles with elevated cholesterol levels only. The separate effects of EPA, DHA, and EPA/DHA were enhanced when used in combination with statin therapy, including atorvastatin, atorvastatin metabolite, simvastatin, or rosuvastatin. The most potent antioxidant capacity was observed with EPA and the active metabolite of atorvastatin.

      "Statins are also lipophilic, in general," Mason told heartwire, "and one statin, in particular atorvastatin and its active metabolite, is known to be a very good antioxidant. We've published that separately in the past. This is where we saw the best effect, although we did see excellent effects with all the statins. The concept is that a lot of people are also taking a statin so there might be some opportunity for synergy."

      • 1 Reply to edvoks
      • Positive effects on markers are good and would have been enough to get new scripts 5-10 years ago. These days its all about on outcomes. Longs got a long wait for reduce it, which may go either way. For the next year, MARINE sales (speed of Lovaza and fibrates script displacement) and NCE are the only drivers of pps. ANCHOR is a huge denominator with greatly unknown numerator.

        Sentiment: Hold

1.51+0.05(+3.42%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.